Shenyang Xingqi Pharmaceutical Co (300573) Fair Value & Analysis
Healthcare · CN · Market cap 13.2B CNY
Fair value as of: Jul 9, 2026
From 24 valuation models · updated 32 days ago
Share price +3.9% over the past month.
A solid business, but screening 24% overvalued on our models.
What matters now
- The model range is unusually wide (¥24.28 to ¥69.96). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (69/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.
How to read this chart
60‑month range ¥18.14 – ¥96.41 · fair‑value band ¥24.28 – ¥69.96 · the ¥42.61 price screens above the ¥32.24 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 9, 2026.
Analysis
Shenyang Xingqi Pharmaceutical Co (300573) currently trades at ¥42.61, while our model-based Fair Value estimate is ¥32.24, implying the stock looks roughly 24.3% overvalued today. The Quality Score stands at 69/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Shenyang Xingqi Pharmaceutical Co generated revenue of 2.6B CNY at a net margin of 28.9%. Revenue grew 27.5% year over year. It earns a return on equity of 38.5%. The balance sheet holds a net cash position of 161M CNY. Fundamentals as of Jul 9, 2026
Our scenario range runs from ¥24.28 (bear case) to ¥69.96 (bull case); at ¥42.61, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 26% below its 52-week high and 28% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -24%, 300573 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (¥63.31) versus Asset-Based (¥3.71). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 69 · Market factors (momentum, volatility) 49
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shenyang Xingqi Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of ophthalmic drugs in the People's Republic of China.
Full company description
Shenyang Xingqi Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of ophthalmic drugs in the People's Republic of China. The company offers myopia prevention and control medications, nutrition and corneal repair drugs, ophthalmic anti-inflammatory and anti-infective drugs, artificial tears and eye lubricants, ophthalmic non-steroidal anti-inflammatory drugs, intraocular rinsing fluids, pupil dilatant and ciliary muscle paralyzers, anti-fatigue medicines, dry eye treatment medicines, mydriatics and cycloplegia drugs, miotics and anti-glaucoma drugs, and intraoperative intraocular irrigation fluids. It also engages in technology development, technical advice, eye hospital, and research and experimental development activities. Shenyang Xingqi Pharmaceutical Co.,Ltd. was founded in 1977 and is based in Shenyang, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shenyang Xingqi Pharmaceutical Co reported revenue of ¥2.5B in FY2025 versus ¥1.0B in FY2021, a compound +24.5%/yr. Reported net income was ¥696M in FY2025, compounding +37.5%/yr from FY2021.
300573 screens 24% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Shenyang Xingqi Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shenyang Xingqi Pharmaceutical Co (300573) overvalued or undervalued?
What is the fair value of 300573?
What is the quality score of 300573?
What is the revenue of Shenyang Xingqi Pharmaceutical Co (300573)?
What is the net profit margin of 300573?
Does Shenyang Xingqi Pharmaceutical Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shenyang Xingqi Pharmaceutical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.